NEW YORK ─ Microbix Biosystems said on Monday that it has inked an agreement that enables SDT Molecular to distribute Microbix's quality assessment products, or QAPs, in Hong Kong, Indonesia, Malaysia, and Singapore.
Under the agreement, SDT will provide customer service, sales and marketing, distribution, and logistical support for Microbix's QAPs.
Financial and other terms of the agreement were not disclosed.
Singapore-based SDT provides products to hospitals and clinical laboratories, has a “strong track record in molecular diagnostics” involving a focus on infectious and genetic diseases, and has experience in product development, manufacturing, distribution, and customer support, Microbix said.
Mississauga, Ontario-based Microbix said it provides more than 70 quality assessment products to support the accuracy of infectious disease diagnostic tests. SDT is particularly interested in its QAPs used to support the accuracy of SARS-CoV-2 molecular and antigen tests as well as tests for the human papilloma virus and Mycoplasma genitalium, Microbix said.
Microbix has also added QAPs to support the accuracy of RT-PCR tests for the Brazilian, South African, and UK SARS-CoV-2 variants of concern.
"With the recent COVID-19 pandemic, we have seen and foresee growing demand in quality control reagents for infectious diseases, especially as more diagnostic laboratories and manufacturers are being established," Tan Shirley, founder and CEO of SDT, said in a statement.